Bio-Techne Corporation has announced that Asuragen, one of its brands, has released a cutting-edge assay designed for the precise detection of ESR1 mutations. These genetic alterations in the ESR1 gene are associated with HR+ metastatic breast cancer. The research-use-only assay package combines a qPCR detection kit with tools for cell-free DNA and exosomal RNA isolation, showcased at Asuragen’s exhibit (Booth #1429) during the San Antonio Breast Cancer Symposium starting December 10.
Though ESR1 gene mutations are rarely found in patients before beginning cancer treatment, they emerge in up to 40% of patients undergoing endocrine therapy for HR+ metastatic breast cancer. Rapid identification of these mutations is critical for healthcare providers to recognize signs of treatment resistance and make timely interventions. However, many molecular testing methods currently lack the effectiveness needed to consistently and affordably detect these variations.
The newly launched Assay from Asuragen, featuring the QuantideX qPCR ESR1 exoMutation Kit combined with the ExoLution Plus cfDNA + exoRNA Isolation Kit, has been engineered to detect 11 specific ESR1 ligand-binding domain mutations with exceptional sensitivity. Compatible with standard qPCR technology, it is easy to integrate without additional expenses associated with adopting new systems. By tapping into signals from both cell-free DNA and exosomal RNA, this assay offers unprecedented sensitivity previously obtainable only with more complex, higher-cost technologies.
Dr. Matt McManus, President of Bio-Techne’s Diagnostics and Spatial Biology Segment, stated, “As more promising drugs aimed at ESR1 mutations enter clinical trials, it’s essential for laboratory professionals to monitor these mutations in patients treated with aromatase inhibitors and other endocrine therapies. Our expertise in developing highly sensitive, qPCR-based assays, coupled with our proficiency in exosomal data extraction, positions Bio-Techne as a leader in offering superior, accessible, and multiplexed solutions for ESR1 mutation detection in research labs around the world.”
The ESR1 mutation assay by Asuragen is intended solely for research purposes and not for clinical diagnostic applications.
Bio-Techne Corporation is a global entity known for delivering innovative life sciences tools and bioactive agents that support research initiatives and clinical diagnostic advancements. Bio-Techne’s offerings facilitate scientific exploration into biological mechanisms and the nature and progression of diseases.